Eli Lilly
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
Eli Lilly’s Alzheimer’s Treatment Kisunla Secures Fourth Major Market Approval with NMPA Authorization in China
2024-12-18
China’s Laekna Joins Forces with Weight-Loss Giant Lilly on Muscle-Preserving Obesity Drug in Expanding $150B Market
2024-11-21
FDA to Reassess Shortage Status of Key Obesity Drugs; Compounding Stocks Out of the Red—for Now
2024-10-16
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24